TY - JOUR
T1 - Essential medicines for childhood cancer in Europe
T2 - a pan-European, systematic analysis by SIOPE
AU - Essential Medicines Group
AU - Otth, Maria
AU - Brack, Eva
AU - Kearns, Pamela R.
AU - Kozhaeva, Olga
AU - Ocokoljic, Marko
AU - Schoot, Reineke A.
AU - Vassal, Gilles
AU - Achini, Federica
AU - Balduzzi, Adriana
AU - Beck Popovic, Maja
AU - Beishuizen, Auke
AU - Bergamaschi, Luca
AU - Biondi, Andrea
AU - Bourdeaut, Franck
AU - Braicu, Elena
AU - Brok, Jesper
AU - Brugières, Laurence
AU - Burke, Amos
AU - Calaminus, Gabriele
AU - Casanova, Michela
AU - Choucair, Marie Louise
AU - Cleirec, Morgane
AU - Corbaciouglu, Selim
AU - Correa Llano, Maria Genoveva
AU - De Rojas, Teresa
AU - Domínguez Pinilla, Nerea
AU - Elmaraghi, Caroline
AU - Ferrari, Andrea
AU - Fossa, Alexander
AU - Gaspar, Nathalie
AU - Herold, Nikolas
AU - Karapiperi, Kyriaki
AU - Karu, Maarja
AU - Kjærsgaar, Mimi
AU - Knörr, Fabian
AU - Koenig, Christa
AU - Kranjcec, Izabela
AU - Krawczyk, Malgorzata
AU - Lehmberg, Kai
AU - Lehrnbecher, Thomas
AU - Lunesink, Maaike
AU - Massano, Davide
AU - Matijasic, Nuša
AU - Merks, Hans
AU - Metzler, Markus
AU - Michalski, Anthony
AU - Minkov, Milen
AU - Morland, Bruce
AU - Niktoreh, Naghmeh
AU - Stutterheim, Janine
N1 - Copyright © 2022 Elsevier Ltd. All rights reserved.
PY - 2022/12
Y1 - 2022/12
N2 - Background: Shortages and unequal access to anticancer medicines for children and adolescents are a reality in Europe. The aim of the European Society for Paediatric Oncology (SIOPE) Essential Anticancer Medicines Project was to provide a list of anticancer medicines that are considered essential in the treatment of paediatric cancers to help ensure their continuous access to all children and adolescents with cancer across Europe. Methods: This pan-European project, done between Jan 20, 2020, and Feb 18, 2022, was designed to be a systematic collection and review of treatment protocols and strategies that are used to treat childhood cancer in Europe. We formed 16 working groups on the basis of paediatric cancer types, and which were based on the existing SIOPE Clinical Trial Groups. Workings groups consisted of representatives from the SIOPE Clinical Trial Groups, Young SIOPE members, and senior paediatric oncology experts. Each group collected existing treatment protocols that are used to treat the respective cancer types in Europe. Medicines from the standard group of each protocol were extracted. For medicines not on the WHO Essential Medicines List for children (EMLc) 2017, working groups did a literature search to determine whether the medicines should be defined as essential, promising, or neither essential nor promising. Each group provided an individual summary, and all medicines that were considered essential by at least one group were combined in a joint list. Findings: The working groups identified 73 treatment protocols used in Europe and defined 66 medicines as essential. For several newer medicines, such as kinase inhibitors or tisagenlecleucel, the supporting evidence was insufficient to consider them essential, so these medicines were defined as promising. 25 medicines were considered promising by at least one working group. 22 (33%) of the 66 essential and none of the promising medicines were included in the WHO EMLc 2017. The WHO EMLc 2021 included two new medicines (everolimus and vinorelbine) following applications we made as a result of this project. Interpretation: Medicines that were defined as essential within this project should be available for the treatment of childhood and adolescent cancer continuously and across Europe. This list can be used to support and guide stakeholders and policy makers in negotiations on a national and European level regarding shortages, accessibility, and affordability of these medicines. Funding: None.
AB - Background: Shortages and unequal access to anticancer medicines for children and adolescents are a reality in Europe. The aim of the European Society for Paediatric Oncology (SIOPE) Essential Anticancer Medicines Project was to provide a list of anticancer medicines that are considered essential in the treatment of paediatric cancers to help ensure their continuous access to all children and adolescents with cancer across Europe. Methods: This pan-European project, done between Jan 20, 2020, and Feb 18, 2022, was designed to be a systematic collection and review of treatment protocols and strategies that are used to treat childhood cancer in Europe. We formed 16 working groups on the basis of paediatric cancer types, and which were based on the existing SIOPE Clinical Trial Groups. Workings groups consisted of representatives from the SIOPE Clinical Trial Groups, Young SIOPE members, and senior paediatric oncology experts. Each group collected existing treatment protocols that are used to treat the respective cancer types in Europe. Medicines from the standard group of each protocol were extracted. For medicines not on the WHO Essential Medicines List for children (EMLc) 2017, working groups did a literature search to determine whether the medicines should be defined as essential, promising, or neither essential nor promising. Each group provided an individual summary, and all medicines that were considered essential by at least one group were combined in a joint list. Findings: The working groups identified 73 treatment protocols used in Europe and defined 66 medicines as essential. For several newer medicines, such as kinase inhibitors or tisagenlecleucel, the supporting evidence was insufficient to consider them essential, so these medicines were defined as promising. 25 medicines were considered promising by at least one working group. 22 (33%) of the 66 essential and none of the promising medicines were included in the WHO EMLc 2017. The WHO EMLc 2021 included two new medicines (everolimus and vinorelbine) following applications we made as a result of this project. Interpretation: Medicines that were defined as essential within this project should be available for the treatment of childhood and adolescent cancer continuously and across Europe. This list can be used to support and guide stakeholders and policy makers in negotiations on a national and European level regarding shortages, accessibility, and affordability of these medicines. Funding: None.
KW - Adolescent
KW - Child
KW - Humans
KW - Neoplasms/drug therapy
KW - Medical Oncology
KW - Europe
KW - Drugs, Essential/therapeutic use
KW - Antineoplastic Agents/therapeutic use
UR - http://www.scopus.com/inward/record.url?scp=85142860753&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(22)00623-4
DO - 10.1016/S1470-2045(22)00623-4
M3 - Article
C2 - 36332647
AN - SCOPUS:85142860753
SN - 1470-2045
VL - 23
SP - 1537
EP - 1546
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 12
ER -